15 July 2002
Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives
Arnab Roy Chowdhury, Suparna Mandal, Bidyottam Mittra, Shalini Sharma, Sibabrata Mukhopadhyay, Hemanta K. MajumderMed Sci Monit 2002; 8(7): BR254-260 :: ID: 13614
Abstract
Background: Betulinic acid, a naturally abundant, plant derived, pentacyclic triterpenoid possesses anti- HIV, anti-malarial and anti-inflammatory properties and has recently emerged as a potent
anti-tumor compound. This study explores the mode of action of betulinic acid on eukaryotic topoisomerase I and identifies the major functional group responsible along with more potent derivatives.
Material/Methods: Topoisomerase I relaxation activity was electrophoretically measured by the decreased mobility of the relaxed monomers followed by ethidium bromide staining. DNA cleavage was studied by electrophoretic separation of the nicked monomers from the relaxed and supercoiled monomers in presence of ethidium bromide. In-vivo DNA cleavage was studied in blasted mouse splenocytes by the SDS-K+ trapping of 3H-DNA-topoisomerase I-camptothecin ternary complex.
Results: Betulinic acid exerts its inhibitory effect by preventing topoisomerase I-DNA interaction as a result of which the ‘cleavable complex’ is not formed. In consequence, it also acts as an antagonist
to camptothecin-mediated cleavage. A series of analogues modified at C-3, C-17 and C- 20 positions of betulinic acid were subsequently assayed for inhibition of topoisomerase I catalytic activity. Replacement of the 17-carboxylic group reduces the inhibitory effect and decarboxylation leads to the complete loss of inhibitory effect.
Conclusion: This study is the first detail report of betulinic acid as a very potent inhibitior of eukaryotic topoisomerase I and highlights the necessity of the carboxylic functional group. Dihydro betulinic acid is the most potent (IC50=0.5 µM) pentacyclic triterpenoid to inhibit eukaryotic topoisomerase I till date and can be exploited as a strong candidate for anti-tumor drug designing.
Keywords: Antineoplastic Agents, Phytogenic - chemistry, Antineoplastic Agents, Phytogenic - isolation & purification, Antineoplastic Agents, Phytogenic - metabolism, Camptothecin - metabolism, DNA - metabolism, DNA Topoisomerases, Type I, Eukaryotic - antagonists & inhibitors, DNA Topoisomerases, Type I, Eukaryotic - metabolism, DNA-Binding Proteins - metabolism, Enzyme Inhibitors - chemistry, Enzyme Inhibitors - isolation & purification, Enzyme Inhibitors - metabolism, Macromolecular Substances, Molecular Structure, Plant Extracts - chemistry, Plant Extracts - metabolism, Protein Binding, Triterpenes - chemistry, Triterpenes - isolation & purification, Triterpenes - metabolism
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Clinical Research
Use of The Mirror-Image Technique for Patient-Specific Reconstruction of Cuboid FracturesMed Sci Monit In Press; DOI: 10.12659/MSM.947437
Laboratory Research
Retention of 3-D-Printed, Milled, and Conventionally Fabricated Occlusal SplintsMed Sci Monit In Press; DOI: 10.12659/MSM.947342
Review article
A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitor...Med Sci Monit In Press; DOI: 10.12659/MSM.949300
Clinical Research
Buccal Acupuncture Reduces the Dose of Sufentanil Needed in Laparoscopic Gynecological SurgeryMed Sci Monit In Press; DOI: 10.12659/MSM.947088
Most Viewed Current Articles
17 Jan 2024 : Review article 7,932,846
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,905
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 29,808
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 23,790
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912